Mary H Samuels1, Irina Kolobova, Anne Smeraglio, Dawn Peters, Jeri S Janowsky, Kathryn G Schuff. 1. Division of Endocrinology, Diabetes, and Clinical Nutrition (M.H.S., I.K., A.S., K.G.S.), Division of Biostatistics (D.P.), and Department of Behavioral Neurosciences (J.S.J.), Oregon Health & Science University, Portland, Oregon 97239.
Abstract
CONTEXT: TSH-suppressive doses of levothyroxine (L-T4) have adverse effects on bone and cardiac function, but it is unclear whether central nervous system function is also affected. OBJECTIVE: The aim of the study was to determine whether women receiving TSH-suppressive L-T4 doses have decrements in health status, mood, or cognitive function. DESIGN AND SETTING: A cross-sectional comparison was made among three groups of women in an academic medical center research clinic. PATIENTS: Twenty-four women receiving chronic TSH-suppressive L-T4 doses, 35 women receiving chronic replacement L-T4 doses, and 20 untreated control women participated in the study. INTERVENTIONS: Subjects underwent testing at a single outpatient visit. MAIN OUTCOME MEASURES: We measured health status (SF-36), mood (Profile of Mood States, Symptom Checklist 90-R, Affective Lability Scale), and cognitive function (declarative memory [Paragraph Recall], working memory [N-back, Subject Ordered Pointing], motor learning [Pursuit Rotor, Motor Sequence Learning Test], and executive function [Letter Cancellation Test, Trail Making Test, Iowa Gambling Test]). RESULTS: Women receiving TSH-suppressive or replacement L-T4 doses had decrements in health status and mood compared to healthy controls. These decrements were more pronounced in women receiving replacement, rather than suppressive, L-T4 doses. Memory and executive function were not affected in either treated group, compared to healthy controls. CONCLUSIONS: Women receiving TSH-suppressive doses of L-T4 do not have central nervous system dysfunction due to exogenous subclinical thyrotoxicosis, but TSH-suppressed and L-T4-replaced women have slight decrements in health status and mood that may be related to self-knowledge of the presence of a thyroid condition or other uncharacterized factors. These mood alterations do not impair cognitive function.
CONTEXT: TSH-suppressive doses of levothyroxine (L-T4) have adverse effects on bone and cardiac function, but it is unclear whether central nervous system function is also affected. OBJECTIVE: The aim of the study was to determine whether women receiving TSH-suppressive L-T4 doses have decrements in health status, mood, or cognitive function. DESIGN AND SETTING: A cross-sectional comparison was made among three groups of women in an academic medical center research clinic. PATIENTS: Twenty-four women receiving chronic TSH-suppressive L-T4 doses, 35 women receiving chronic replacement L-T4 doses, and 20 untreated control women participated in the study. INTERVENTIONS: Subjects underwent testing at a single outpatient visit. MAIN OUTCOME MEASURES: We measured health status (SF-36), mood (Profile of Mood States, Symptom Checklist 90-R, Affective Lability Scale), and cognitive function (declarative memory [Paragraph Recall], working memory [N-back, Subject Ordered Pointing], motor learning [Pursuit Rotor, Motor Sequence Learning Test], and executive function [Letter Cancellation Test, Trail Making Test, Iowa Gambling Test]). RESULTS:Women receiving TSH-suppressive or replacement L-T4 doses had decrements in health status and mood compared to healthy controls. These decrements were more pronounced in women receiving replacement, rather than suppressive, L-T4 doses. Memory and executive function were not affected in either treated group, compared to healthy controls. CONCLUSIONS:Women receiving TSH-suppressive doses of L-T4 do not have central nervous system dysfunction due to exogenous subclinical thyrotoxicosis, but TSH-suppressed and L-T4-replaced women have slight decrements in health status and mood that may be related to self-knowledge of the presence of a thyroid condition or other uncharacterized factors. These mood alterations do not impair cognitive function.
Authors: B Biondi; E A Palmieri; S Fazio; C Cosco; M Nocera; L Saccà; S Filetti; G Lombardi; F Perticone Journal: J Clin Endocrinol Metab Date: 2000-12 Impact factor: 5.958
Authors: Osvaldo P Almeida; Helman Alfonso; Leon Flicker; Graeme Hankey; S A Paul Chubb; Bu B Yeap Journal: Am J Geriatr Psychiatry Date: 2011-09 Impact factor: 4.105
Authors: Annenienke C van de Ven; Romana T Netea-Maier; Femmie de Vegt; H Alec Ross; Fred C G J Sweep; Lambertus A Kiemeney; Ad R Hermus; Martin den Heijer Journal: Thyroid Date: 2012-10-19 Impact factor: 6.568
Authors: Sarah J Peterson; Anne R Cappola; M Regina Castro; Colin M Dayan; Alan P Farwell; James V Hennessey; Peter A Kopp; Douglas S Ross; Mary H Samuels; Anna M Sawka; Peter N Taylor; Jacqueline Jonklaas; Antonio C Bianco Journal: Thyroid Date: 2018-04-05 Impact factor: 6.568
Authors: Omar Saeed; Lori J Bernstein; Rouhi Fazelzad; Mary Samuels; Lynn A Burmeister; Lehana Thabane; Shereen Ezzat; David P Goldstein; Jennifer Jones; Anna M Sawka Journal: J Cancer Surviv Date: 2019-04-04 Impact factor: 4.442
Authors: Mi Sook Jung; Moira Visovatti; Mijung Kim; Kyengin Cha; Nondumiso Dlamini; Xirong Cui Journal: Support Care Cancer Date: 2022-08-03 Impact factor: 3.359
Authors: Mary H Samuels; Irina Kolobova; Anne Smeraglio; Meike Niederhausen; Jeri S Janowsky; Kathryn G Schuff Journal: Thyroid Date: 2016-07-25 Impact factor: 6.568